Clinical Trial Update: MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of the MEK inhibitor mirdametinib for Neurofibromatosis type 1–associated plexiform neurofibromas has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: SpringWorks Therapeutics, Inc. | Conditions: Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-07